ProfileGDS5678 / 1448552_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 73% 73% 72% 73% 74% 78% 73% 73% 73% 74% 73% 73% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7630274
GSM967853U87-EV human glioblastoma xenograft - Control 24.7846873
GSM967854U87-EV human glioblastoma xenograft - Control 34.7670873
GSM967855U87-EV human glioblastoma xenograft - Control 44.6972772
GSM967856U87-EV human glioblastoma xenograft - Control 54.7132873
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7737874
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.191178
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7420873
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7325173
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7451773
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8036674
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7922673
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.722673
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.970375